Vaxart, Inc

Description

platform technology that will let almost any vaccine be delivered orally. Our initial applications include Avian Influenza, annual influenza, second-generation oral versions of existing vaccines, and unmet needs. The company is currently testing an avian flu vaccine in animal models and is working toward a clinical trial in 2010. Advantages of the Vaxart Vaccine Platform -Oral delivery is strongly preferred by care providers and patients. -New vaccines can be created very quickly to protect against new circulating avian flu strains, other emerging pathogens, or biodefense threats. -Vaxart uses efficient and standardized manufacturing methods, with essentially the same process for every Vaxart vaccine. -Vaxart vaccines retain potency for more than a month at room temperature, potentially allowing final distribution without refrigeration or the need for administration by trained medical staff. -Vaxart vaccines generate antigen-specific killer T-cell and IgA antibody responses, as well as IgG antibody responses. -Oral vaccination with live adenovirus (to prevent respiratory adenovirus infection) has an excellent safety record in millions of subjects. News: March 2010: Vaxart announces completion of Series B financing. Read more... September 2009: NIAID divison of NIH awards $2.8 million SBIR Phase II grant to Vaxart to continue to develop oral vaccine platform. Read more... June 2009: Vaxart demonstrates strong immune responses against H1N1 (Swine Flu) in animal studies. May 2009: Vaxart initiates animal testing of candidate H1N1 vaccine.

Products & services

Similar companies nearby